IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 149 filers reported holding IMMUNOVANT INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $21,558,900 | -67.1% | 1,390,000 | -62.4% | 0.40% | -69.4% |
| Q4 2022 | $65,563,530 | +118.7% | 3,693,720 | -31.2% | 1.29% | +119.2% |
| Q3 2022 | $29,979,000 | +43.1% | 5,372,512 | 0.0% | 0.59% | +31.7% |
| Q2 2022 | $20,953,000 | -29.2% | 5,372,512 | 0.0% | 0.45% | -3.4% |
| Q1 2022 | $29,603,000 | -29.8% | 5,372,512 | +8.5% | 0.46% | -13.9% |
| Q4 2021 | $42,174,000 | -2.0% | 4,950,000 | 0.0% | 0.54% | -4.9% |
| Q3 2021 | $43,016,000 | +20.7% | 4,950,000 | +46.8% | 0.57% | +18.4% |
| Q2 2021 | $35,631,000 | -10.2% | 3,370,994 | +36.3% | 0.48% | -18.5% |
| Q1 2021 | $39,667,000 | -7.9% | 2,473,000 | +165.3% | 0.59% | -10.9% |
| Q4 2020 | $43,049,000 | +31.3% | 932,000 | 0.0% | 0.66% | +2.8% |
| Q3 2020 | $32,797,000 | +115.2% | 932,000 | +48.9% | 0.64% | +94.0% |
| Q2 2020 | $15,242,000 | – | 625,950 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |